Popular Trials
Antiviral
JNJ-73763989 + Antivirals for Hepatitis B and D Co-Infection
This trial is testing a new drug called JNJ-73763989 combined with an existing medication to treat hepatitis D virus (HDV). The goal is to see if this combination works better than the current treatment alone. The new drug is expected to enhance the effectiveness of the existing medication.
Anti-viral
Preemptive Mavyret Therapy for Hepatitis C in Organ Transplant Recipients
This trial is testing if using two medicines together can stop Hepatitis C from spreading to people who get an organ transplant from a donor with Hepatitis C. The goal is to protect the new organ recipient from getting infected by the virus.
Direct Acting Antiviral
Hepatitis C Kidneys Transplantation for Kidney Failure
This trial will study whether it is safe to transplant kidneys from donors with hepatitis C into recipients who do not have the virus. One-year allograft function and one-year risk of CMV infection will be compared between THINKER-NEXT kidney transplant recipients and matched recipients who received hepatitis C uninfected kidney transplants. The mortality rate of kidney transplant candidates who enroll in THINKER-NEXT and consent to offers of kidneys from HCV-infected donors will be compared to matched wait-listed patients who do not consent to receive HCV-infected kidneys. Lastly, renal pathologic findings will be compared among HC
Hepatitis C Positive Liver Transplants for Liver Transplant Recipients
This trial is testing the safety and efficacy of transplanting livers from donors who are either positive or negative for the Hepatitis C virus. Treatment and prophylaxis will be administered to the recipients based on the donor's status.
Antiviral
Sofosbuvir/Velpatasvir for Kidney Transplant Recipients
This trial is testing the safety and efficacy of transplanting kidneys from donors who are either hepatitis C seropositive and non-viremic, or seropositive and viremic, to recipients who are seronegative. Treatment and prophylaxis will be administered using a transmission-triggered approach for the first scenario and a prophylaxis approach for the later scenario.
Popular Filters
Trials for HCV Patients
Direct Acting Antiviral Agent
Epclusa for Chronic Hepatitis C
This trial will study why some people still have liver complications after being cured of hepatitis C. Eligible participants will have different tests and some will take medication for 12 weeks. Then they will have follow-up visits for up to 10 years.
Sofosbuvir/Velpatasvir for Heart Transplant
This trial is testing the safety and efficacy of transplanting hearts from HCV seropositive non-viremic and HCV seropositive viremic donors to HCV seronegative recipients. Treatment and prophylaxis will be used to prevent HCV transmission.
Cancer Vaccine
DNA Vaccine for Chronic Hepatitis C
This trial studies the side effects and best dose of the DNA vaccine in treating patients with HCV infection. The vaccine may help the body build an effective immune response to kill cancer cells that express HCV infection.
Bcl-2 Inhibitor
Navitoclax + Sorafenib for Cancer
This trial is testing navitoclax and sorafenib tosylate in patients whose solid tumors have returned or don't respond to treatment. The drugs aim to stop cancer growth by blocking essential enzymes. Sorafenib has shown effectiveness in several cancers. The study will determine the best dose and monitor side effects.
Chemotherapy
MTL-CEBPA + Sorafenib for Liver Cancer
This trial is testing an experimental treatment (MTL-CEBPA) in combination with a standard of care treatment (sorafenib) in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
Trials for Non-alcoholic Fatty Liver Disease Patients
Thiazolidinedione
Rosiglitazone for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the efficacy of rosiglitazone alone compared with rosiglitazone plus metformin or rosiglitazone plus losartan in the treatment of biopsy proven nonalcoholic steatohepatitis (NASH). This study was designed to answer the question: are there differences in the efficacy (as measured by histopathology and insulin resistance) of three different therapeutic modalities used to treat NASH?
Thyroid hormone receptor agonist
MGL-3196 for Non-alcoholic Fatty Liver Disease
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in patients with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Microbiota Therapy
Fecal Microbiota Transplantation for Non-alcoholic Fatty Liver Disease
Nonalcoholic steatohepatitis (NASH) is common, may progress to cirrhosis and is predicted to become a leading indication for liver transplantation in the near future. Though often associated with obesity and the metabolic syndrome, our current understanding of disease development is limited and there are few therapeutic options. Imbalance of gut bacteria is suspected to play a key role driving the progression of fatty liver disease and there is hope manipulation of these bacteria may be beneficial. This study will determine if fecal microbiota transplantation, using stool from lean donors, is an effective and safe treatment for NASH.
GLP-1 Receptor Agonist
Semaglutide + Cilofexor/Firsocostat for NASH with Cirrhosis
This trial is testing a combination of medications to help people with severe liver disease caused by NASH. The treatment includes semaglutide, which helps control blood sugar, and a mix of cilofexor and firsocostat, which reduce liver inflammation and fat. The goal is to see if these drugs can improve liver health and resolve NASH.
Phase 3 Trials
Monoclonal Antibodies
VAY736 for Advanced Cancer
This trial is testing a new medication called VAY736 to help adults with autoimmune hepatitis who haven't responded to or can't tolerate standard treatments. The goal is to see if VAY736 can reduce liver inflammation and improve liver function.
Nucleoside Reverse Transcriptase Inhibitor
Antiviral Therapy for Hepatitis B Transmission Prevention
This trial tests antiviral drugs to prevent hepatitis B transmission from mothers to babies. It focuses on high-risk pregnant women and their newborns in Africa. The drugs lower virus levels in mothers and protect babies until they are vaccinated. One of the drugs, Tenofovir disoproxil fumarate (TDF), has been studied for its ability to prevent the spread of hepatitis B from mothers to their babies.
Antiviral
HCV-Positive Organ Transplant Safety
This trial will test if it's safe to transplant organs from donors with HCV to recipients who don't have HCV. The recipient will take medication before and after the transplant. If successful, this could provide a large number of organs for transplant.
Trials With No Placebo
Direct Acting Antiviral Agent
Epclusa for Chronic Hepatitis C
This trial will study why some people still have liver complications after being cured of hepatitis C. Eligible participants will have different tests and some will take medication for 12 weeks. Then they will have follow-up visits for up to 10 years.
Sofosbuvir/Velpatasvir for Heart Transplant
This trial is testing the safety and efficacy of transplanting hearts from HCV seropositive non-viremic and HCV seropositive viremic donors to HCV seronegative recipients. Treatment and prophylaxis will be used to prevent HCV transmission.
Cancer Vaccine
DNA Vaccine for Chronic Hepatitis C
This trial studies the side effects and best dose of the DNA vaccine in treating patients with HCV infection. The vaccine may help the body build an effective immune response to kill cancer cells that express HCV infection.
Bcl-2 Inhibitor
Navitoclax + Sorafenib for Cancer
This trial is testing navitoclax and sorafenib tosylate in patients whose solid tumors have returned or don't respond to treatment. The drugs aim to stop cancer growth by blocking essential enzymes. Sorafenib has shown effectiveness in several cancers. The study will determine the best dose and monitor side effects.
View More Related Trials
Frequently Asked Questions
Introduction to autoimmune hepatitis
What are the top hospitals conducting autoimmune hepatitis research?
When it comes to advancing the understanding and treatment of autoimmune hepatitis, several top hospitals are leading the way. In Boston, Massachusetts General Hospital takes center stage with five active clinical trials focused on this condition. This renowned institution is no stranger to groundbreaking research and has been making strides in autoimmune hepatitis since recording its first trial in 2016. Meanwhile, in Cleveland, the prestigious Cleveland Clinic is also actively involved in five ongoing trials for autoimmune hepatitis. Although they have not conducted any previous specific trials for this condition, their expertise and commitment to research make them an important player in the field.
Another significant contributor to autoimmune hepatitis research is the National Institutes of Health Clinical Center located in Bethesda. With four active clinical trials currently underway, this esteemed institution plays a crucial role in advancing our knowledge of this complex disease. Similarly, at Washington University School of Medicine in Saint Louis, researchers are conducting four active clinical trials while having accomplished one all-time trial focusing on autoimmune hepatitis since their inaugural study began just a few years ago.
Rounding out the list is UPMC (University of Pittsburgh Medical Center) where three cutting-edge clinical trials targeting autoimmune hepatitis are currently taking place. While they haven't conducted any previous studies dedicated solely to this condition yet holding immense potential as a highly regarded medical center specializing across various fields.
These hospitals represent beacons of hope for individuals living with autoimmune hepatitis by providing access to innovative treatments and contributing invaluable data that will ultimately shape future care approaches globally
Which are the best cities for autoimmune hepatitis clinical trials?
When it comes to autoimmune hepatitis clinical trials, several cities emerge as leading hubs for research and development. New york City boasts 38 ongoing trials focusing on various treatments like DUR-928 30 mg and BNT162b2. Boston, Massachusetts follows closely behind with 25 active studies exploring interventions such as DUR-928 30 mg and Rozanolixizumab. Miami, Florida, Houston, Texas, and Los Angeles, California also show promise with their respective numbers of active trials. These cities provide individuals with autoimmune hepatitis access to cutting-edge research opportunities that pave the way for improved treatment options and better outcomes in the future.
Which are the top treatments for autoimmune hepatitis being explored in clinical trials?
Autoimmune hepatitis is a complex condition, but researchers are actively exploring various treatments through clinical trials. Among the top contenders are:
- Rituximab: 5 active trials, 93 all-time autoimmune hepatitis trials, first listed in 1997
- Tofacitinib: 3 active trials, 36 all-time autoimmune hepatitis trials, first listed in 2011
- Mycophenolate mofetil: 2 active trials for autoimmune hepatitis, involved in a total of 65 clinical studies since its introduction in the year2000.
What are the most recent clinical trials for autoimmune hepatitis?
Recent clinical trials have brought hope to individuals battling autoimmune hepatitis, as researchers explore new treatment options. One such trial focuses on the depletion of CD3/CD19 in an autologous stem cell transplant for autoimmune hepatitis. By targeting specific cells involved in the immune response, this approach aims to restore balance and alleviate symptoms. Another study examines the efficacy of HepB mAb19 administered intravenously for autoimmune hepatitis, evaluating its potential benefits in managing the condition. Additionally, Panzyga IVIG is being investigated as a potential therapy option, exploring its ability to modulate the immune system and improve liver function in patients with autoimmune hepatitis. These ongoing trials pave the way towards improved treatments that may enhance outcomes for those affected by this challenging condition.
What autoimmune hepatitis clinical trials were recently completed?
Recently completed clinical trials for autoimmune hepatitis have brought promising advancements in the field. Notably, a trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases investigated the efficacy of budesonide treatment, concluding in March 2021. Another significant milestone was reached when a trial exploring mycophenolate mofetil as a potential therapy was completed in January 2021. The completion of these trials underscores ongoing efforts to find effective treatments for autoimmune hepatitis and offers hope to patients affected by this challenging condition.